| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2011: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2010: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2009: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Research Abstract |
We examined AQP expression of gall bladder cancer by tissue microarray. In gall bladder cancer, expression of AQP-1 and AQP-5 was observed in 41% and 59% respectively. AQP-5 expression had inverse association with depth of tumor and positive association with gemcitabine sensitivity. Thus, the patients with positive AQP-5 expression had favorable prognosis. SiRNA treatment for AQP-5 positive gall bladder cancer cell line(NOZ-1) inhibited the growth, invasion and mobility of the cells. We identified several miRNAs that can predict Gemcitabine sensitivity of NOZ-1 by microarray analysis. We also identified the target proteins of detected miRNA. Our results suggest that AQP-5 is promising target of gall bladder cancer treatment.
|
